[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kupando GmbH\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100640027","phase-1-a-first-in-human-study-to-evaluate-the-safety-pharmacokinetics-and-pharmacodynamics-of-kup-101a-in-patients-with-selected-advanced-solid-tumors-100640027",false,"NCT07600476","A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* Histologically confirmed cancer with evidence of advanced disease for which no other standard treatment is available\n* ECOG Performance status of 0 to 2\n* Adequate hematological, renal, and hepatic organ function\n\nExclusion Criteria:\n\n* Previous systemic treatment with TLR agonists, with the exception of TLR agonists used as vaccine adjuvants.\n* Known additional malignancy that is progressing or requires active treatment\n* Diagnosis of immunodeficiency\n* Active autoimmune disease not caused by prior anticancer treatment that required systemic immunosuppressive treatment in the past 2 years\n* Active autoimmune disease caused by prior anticancer treatment, unless currently controlled by replacement therapy only.\n* Any kind of leukemia\n* Previously received an organ transplant (other than corneal transplants) or hematopoietic stem cell transplantation\n* Known active central nervous system metastases and\u002For carcinomatous meningitis\n* Cerebral vascular event within 6 months before Screening\n* Unstable cardiopulmonary status defined by uncontrolled congestive heart failure of New York Heart Association Grade III or IV, unstable angina, or myocardial infarction within 6 months before Screening\n* High grade ocular disease such as uncontrolled glaucoma","ALL","18 Years",{"count":18,"type":19},21,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.",[25,26,27,28,29],"Cutaneous Melanoma","Mucosal Melanoma","Cutaneous Squamous Cell Carcinoma (CSCC)","Merkel Cell Carcinoma of Skin","Basal Cell Carcinoma of Skin",[31,32,33,34,35,36],"TLR4 agonist","TLR7 agonist","TLR4\u002F7 agonist","skin cancer","innate immunity","immunotherapy","RECRUITING","2026-05-13",{"date":40,"type":41},"2026-05-20","ACTUAL",{"date":43,"type":19},"2026-04",{"date":45,"type":19},"2028-12",{"name":47,"class":48},"Kupando GmbH","INDUSTRY",2,""]